| Naplex |
HTN brands - generics |
Unfinished |
2026-06-10 |
dao.vo11017 |
32 |
0 |
edit |
|
| Naplex |
HTN clinical pearls |
Unfinished |
2026-06-09 |
dao.vo11017 |
44 |
0 |
edit |
|
| Naplex |
Asthma |
Unfinished |
2026-06-09 |
dao.vo11017 |
30 |
0 |
edit |
|
| Naplex |
Heart Failure - clinical pearl |
Unfinished |
2026-06-09 |
dao.vo11017 |
67 |
0 |
edit |
|
| Naplex |
Heart Failure - Brands / generics |
Unfinished |
2026-06-09 |
dao.vo11017 |
15 |
0 |
edit |
|
| Naplex |
Dyslipidemia - Clinical pearls |
Unfinished |
2026-06-09 |
dao.vo11017 |
82 |
1 |
edit |
|
| Naplex |
Dyslipidemia - Brands / generics |
Unfinished |
2026-06-09 |
dao.vo11017 |
13 |
0 |
edit |
|
| Naplex |
Anticoagulation - Brands / generics |
Unfinished |
2026-06-09 |
dao.vo11017 |
11 |
0 |
edit |
|
| Naplex |
Anticoagulation - clinical pearl |
Unfinished |
2026-06-09 |
dao.vo11017 |
77 |
0 |
edit |
|
| Naplex |
Renal Disease - brands / generics |
Unfinished |
2026-06-09 |
dao.vo11017 |
3 |
0 |
edit |
|
| Naplex |
Renal Disease - clinical pearl |
Unfinished |
2026-06-09 |
dao.vo11017 |
69 |
0 |
edit |
|
| Naplex |
Asthma - Clinical pearl |
Unfinished |
2026-06-09 |
dao.vo11017 |
63 |
0 |
edit |
|
| Naplex |
Asthma - Brands / generics |
Unfinished |
2026-06-09 |
dao.vo11017 |
36 |
0 |
edit |
|
| Naplex |
COPD - Clinical pearl |
Unfinished |
2026-06-09 |
dao.vo11017 |
34 |
0 |
edit |
|
| Naplex |
COPD - Brands / Generics |
Unfinished |
2026-06-09 |
dao.vo11017 |
20 |
0 |
edit |
|
| Naplex |
PAH-clinical pearl |
Unfinished |
2026-06-09 |
dao.vo11017 |
16 |
0 |
edit |
|
| Naplex |
PAH-brands / generics |
Unfinished |
2026-06-09 |
dao.vo11017 |
5 |
0 |
edit |
|
| Naplex |
Smoking - Clinical pearl |
Unfinished |
2026-06-09 |
dao.vo11017 |
42 |
0 |
edit |
|
| Naplex |
Infectious Diseases I - Clinical pearl |
Unfinished |
2026-06-09 |
dao.vo11017 |
102 |
0 |
edit |
|
| Naplex |
Infectious Diseases II - Clinical pearl |
Unfinished |
2026-06-09 |
dao.vo11017 |
3 |
0 |
edit |
|
| CPJE |
Controlled Substances Acts |
Unfinished |
2026-05-19 |
dao.vo11017 |
52 |
0 |
edit |
|
| CPJE |
CS Part 2: Ordering and Disposal |
Unfinished |
2026-05-19 |
dao.vo11017 |
10 |
0 |
edit |
|
| CPJE |
CS part 3: Prescribing and Dispensing |
Unfinished |
2026-05-22 |
dao.vo11017 |
39 |
0 |
edit |
|
| CPJE |
Auxiliary label |
Unfinished |
2026-05-23 |
dao.vo11017 |
31 |
0 |
edit |
|
| CPJE |
Controlled Substances |
Unfinished |
2026-05-23 |
dao.vo11017 |
40 |
0 |
edit |
|
| Naplex |
Compounding |
Unfinished |
2026-06-07 |
dao.vo11017 |
184 |
0 |
edit |
|
| Naplex |
Diabetes |
Unfinished |
2026-06-09 |
dao.vo11017 |
239 |
0 |
edit |
|